Extracellular Vesicle Membrane Protein Profiling and Targeted Mass Spectrometry Unveil CD59 and Tetraspanin 9 as Novel Plasma Biomarkers for Detection of Colorectal Cancer

Simple Summary It is well recognized that EVs carry many membrane proteins on their surface that can transduce signals to recipient cells and serve as biomarkers/target proteins for the diagnosis /treatment of diseases. Although numerous studies have reported profiling of EV proteins from tumor cells, few efforts have been made to systemically explore tumor cell-derived EV membrane proteins and verify that these membrane proteins are useful plasma biomarkers. The present study explored the EV membrane protein profile in common among CRC cell lines and assessed alterations in the plasma EV proteome of CRC patients compared with healthy subjects. It further identified the plasma EV membrane proteins, CD59 and TSPAN9, as a novel biomarker panel that effectively detected CRC through targeted MS-based quantification of roughly a dozen selected candidate membrane proteins in plasma EV samples from 73 CRC patients and 80 healthy subjects. Extracellular vesicles (EVs) are valuable sources for the discovery of useful cancer biomarkers. This study explores the potential usefulness of tumor cell-derived EV membrane proteins as plasma biomarkers for early detection of colorectal cancer (CRC). EVs were isolated from the culture supernatants of four CRC cell lines by ultracentrifugation, and their protein profiles were analyzed by LC-MS/MS. Bioinformatics analysis of identified proteins revealed 518 EV membrane proteins in common among at least three CRC cell lines. We next used accurate inclusion mass screening (AIMS) in parallel with iTRAQ-based quantitative proteomic analysis to highlight candidate proteins and validated their presence in pooled plasma-generated EVs from 30 healthy controls and 30 CRC patients. From these, we chose 14 potential EV-derived targets for further quantification by targeted MS assay in a separate individual cohort comprising of 73 CRC and 80 healthy subjects. Quantitative analyses revealed significant increases in ADAM10, CD59 and TSPAN9 levels (2.19- to 5.26-fold, p < 0.0001) in plasma EVs from CRC patients, with AUC values of 0.83, 0.95 and 0.87, respectively. Higher EV CD59 levels were significantly correlated with distant metastasis (p = 0.0475), and higher EV TSPAN9 levels were significantly associated with lymph node metastasis (p = 0.0011), distant metastasis at diagnosis (p = 0.0104) and higher TNM stage (p = 0.0065). A two-marker panel consisting of CD59 and TSPAN9 outperformed the conventional marker CEA in discriminating CRC and stage I/II CRC patients from healthy controls, with AUC values of 0.98 and 0.99, respectively. Our results identify EV membrane proteins in common among CRC cell lines and altered plasma EV protein profiles in CRC patients and suggest plasma EV CD59 and TSPAN9 as a novel biomarker panel for detecting early-stage CRC.

Automated summary

A study found that membrane proteins CD59 and TSPAN9 derived from colorectal cancer (CRC) cells are novel biomarkers for the early detection of CRC. Quantitative analysis of EV samples from 73 CRC patients and 80 healthy subjects identified CD59 and TSPAN9 as potential markers for distinguishing CRC patients from healthy individuals.